Bortezomib plus dexamethasone as first-line therapy for patients with POEMS syndrome
He H, Zhao D, Jiang H, et al.
Ann Hematol · 2021
Grade Bcohortn=69
Key Findings
- ●Best neurologic response 88.1%
- ●Hematologic CR 46.4%, VEGF response 71.2%
- ●Only 2 patients with grade 1 bortezomib-induced neuropathy (reversible)
- ●No treatment-related deaths
Referenced in (1 disease)
ID: pmid-34331562DOI: 10.1007/s00277-021-04616-zPMID: 34331562